Relmada Therapeutics Inc Reaches Analyst Target Price
February 12, 2024 at 11:08 AM EST
In recent trading, shares of Relmada Therapeutics Inc (RLMD) have crossed above the average analyst 12-month target price of $5.42, changing hands for $5.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..